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Bhlhe40 controls cytokine production by T cells and
is essential for pathogenicity in autoimmune
neuroinﬂammation
Chih-Chung Lin1, Tara R. Bradstreet1, Elizabeth A. Schwarzkopf1, Julia Sim2, Javier A. Carrero1, Chun Chou1,
Lindsey E. Cook1, Takeshi Egawa1, Reshma Taneja3, Theresa L. Murphy1, John H. Russell2 & Brian T. Edelson1

TH1 and TH17 cells mediate neuroinﬂammation in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Pathogenic TH cells in EAE must produce
the pro-inﬂammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF).
TH cell pathogenicity in EAE is also regulated by cell-intrinsic production of the immunosuppressive cytokine interleukin 10 (IL-10). Here we demonstrate that mice deﬁcient for the
basic helix–loop–helix (bHLH) transcription factor Bhlhe40 (Bhlhe40  /  ) are resistant to
the induction of EAE. Bhlhe40 is required in vivo in a T cell-intrinsic manner, where it positively regulates the production of GM-CSF and negatively regulates the production of IL-10.
In vitro, GM-CSF secretion is selectively abrogated in polarized Bhlhe40  /  TH1 and TH17
cells, and these cells show increased production of IL-10. Blockade of IL-10 receptor in
Bhlhe40  /  mice renders them susceptible to EAE. These ﬁndings identify Bhlhe40 as a
critical regulator of autoreactive T-cell pathogenicity.
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xperimental autoimmune encephalomyelitis (EAE) serves as
an animal model for the human neuroinﬂammatory disease
multiple sclerosis. Encephalomyelitis in C57BL/6 mice in
response to immunization with a peptide from myelin oligodendrocyte glycoprotein (MOG) is driven by cytokine-producing
autoreactive T helper (TH) cells1. Historically, interferon-g (IFNg)-producing TH1 cells were thought to be responsible for EAE,
but recent evidence has revealed a more important role for
interleukin 17 (IL-17)-producing TH17 cells2,3. Nevertheless,
neither TH1 (IFN-g) nor TH17 (IL-17A, IL-17F, IL-21 and IL-22)
signature cytokines are required for the development of EAE4–7.
Instead, the cytokine granulocyte-macrophage colony stimulating
factor (GM-CSF) has proven to be a critical factor in the
encephalitogenicity of both TH1 and TH17 cells8–12. IL-1 receptor
and IL-23 receptor signalling are required for TH cell production
of GM-CSF during EAE10,11,13.
GM-CSF production by T cells is regulated cell-intrinsically
through the action of transcription factors. Factors that regulate
its transcription include AP-1 family members, NFAT,
NF-kB family members, including c-Rel and NF-kB1, and
RUNX1 (refs 14–19). Recently, Codarri et al.10 reported a
requirement for RORgt for maximal production of GM-CSF by
TH17 cells, although a second report observed no reduction in
GM-CSF secretion by Rorc  /  TH cells in vitro11. TH1 cells also
produce GM-CSF during EAE, yet speciﬁc transcription factors
regulating their production of GM-CSF have not been
identiﬁed12.
Immunoregulatory cytokines, including IL-10, modulate the
development of EAE20. IL-10 is produced by several cell types
during EAE, including autoreactive non-pathogenic TH cells21–27.
IL-10 suppresses effector T cell responses and limits
inﬂammation. IL-10-deﬁcient mice develop more severe EAE
than wild-type (WT) mice28–30. Expression of IL-10 in TH cells
can be regulated by several transcription factors, depending on
the TH cell subset and the cytokine environment31–35. Relevant to
EAE is the production of IL-10 by TH1, TH17, Tr1 cells and T
regulatory cells (Tregs).
Bhlhe40 (also known as Dec1, Stra13, Sharp2 or Bhlhb2)
belongs to a family of basic helix–loop–helix transcriptional
regulators sharing structural features including a basic DNAbinding domain, a helix–loop–helix domain mediating dimerization and a protein–protein interaction ‘Orange domain’36,37.
Members of this family are known to respond to environmental
stimuli and regulate several physiological processes in diverse cell
types, including the cell cycle, apoptosis and differentiation via
their actions as both transcriptional activators and repressors.
Bhlhe40 is expressed in T cells upon T-cell receptor (TCR)
stimulation38. Bhlhe40  /  mice develop a non-fully penetrant
late-onset (age greater than B8 months) lymphoproliferative
disease associated with autoantibodies38,39, which may be due to a
requirement for Bhlhe40 for Treg maintenance during ageing.
Penetrance of this age-related disease appears to be inﬂuenced by
genetic background. How Bhlhe40 regulates effector T-cell
responses is incompletely characterized.
In this study, we show that Bhlhe40  /  mice are resistant to
EAE induction due, at least in part, to a TH cell-intrinsic defect.
TH cells from these mice display nearly normal IFN-g and IL-17A
production in TH1 and TH17 cultures, respectively, and produce
these cytokines after immunization, but fail to mediate EAE.
Instead, transcriptional and phenotypic analyses of Bhlhe40  / 
TH cells reveal that they fail to produce GM-CSF. We also
demonstrate a role for Bhlhe40 in GM-CSF production by gd
T cells. Bhlhe40  /  TH1 and TH17 cells produce increased
amounts of IL-10, consistent with their nonencepahlitogenic
phenotype. Moreover, blockade of IL-10 signalling renders
Bhlhe40  / 
mice
susceptible
to
EAE.
Chromatin
2

immunoprecipitation sequencing (ChIP-Seq) reveals binding of
Bhlhe40 to the Il3/Csf2 and Il10 loci at several sites bound by
other transcriptional regulators. Overall, our results identify
Bhlhe40 as a novel factor regulating GM-CSF and IL-10
production by T cells, and one that is required for autoimmune
neuroinﬂammation.
Results
Bhlhe40-deﬁcient mice are protected from EAE. To examine
the role of Bhlhe40 in autoimmunity, we immunized
Bhlhe40  /  mice with MOG peptide (amino acids 35–55
(MOG(35–55)). Bhlhe40  /  mice were markedly resistant to
EAE (Fig. 1a), showing no leukocyte inﬁltration on histological
examination of spinal cord sections (Fig. 1b). Bhlhe40 was
required by the hematopoietic compartment for EAE susceptibility, since reconstitution of irradiated Bhlhe40  /  mice with
WT bone marrow (BM) caused susceptibility to EAE, whereas
reconstitution of WT mice with Bhlhe40  /  BM engendered
EAE resistance (Fig. 1c). Bhlhe40 is expressed in activated TH cell
subsets (Supplementary Fig. 1a), as previously reported38,40.
Transfer of WT and Bhlhe40  /  TH cells each reconstituted
the T-cell compartment of recipient Rag1  /  mice equally
(Supplementary Fig. 1b), but only WT cells, and not Bhlhe40  / 
cells, allowed development of EAE after immunization (Fig. 1d).
The central nervous system (CNS) from MOG(35–55)immunized Bhlhe40  /  mice had reduced inﬁltrating myeloid
cells (CD45hiCD11b þ ) relative to WT mice. In Bhlhe40  / 
mice, these cells lacked MHC class II expression, as did
resident microglia (CD45intCD11b þ ) (Fig. 2a,b). Immunized
Bhlhe40  /  mice also harboured fewer CNS-inﬁltrating CD4 þ
T cells (Fig. 2c). CNS-inﬁltrating CD4 þ T cells in WT mice
produced IFN-g and IL-17A, while the few CNS-inﬁltrating
CD4 þ T cells in Bhlhe40  /  mice had reduced IFN-g and
IL-17A production (Fig. 2d,e). Notably, WT CD4 þ T cells
produced GM-CSF, but this was reduced by B90% in
Bhlhe40  /  mice (Fig. 2d,e and Supplementary Fig. 2a). WT
and Bhlhe40  /  mice showed a similar low frequency of IL-10producing CD4 þ T cells in the CNS at the peak of disease
(Supplementary Fig. 2b). Bhlhe40  /  mice showed a slight
reduction in the frequency of CNS-inﬁltrating Foxp3 þ CD4 þ
T cells (analysed at day 29 after immunization, Supplementary
Fig. 2c).
gd T cells are known to inﬁltrate the CNS during EAE, and
promote neuroinﬂammation via their production of IL-17 and
GM-CSF13,41. The role of IFN-g production by these cells in this
setting is unclear. Immunized Bhlhe40  /  mice harboured
B30-fold fewer CNS-inﬁltrating gd T cells compared with WT
mice. Bhlhe40  /  gd T cells produced similar levels of IFN-g
and partially reduced levels of IL-17A, but more markedly
reduced levels of GM-CSF (Fig. 2f,g). Together with our
observations on signiﬁcantly reduced GM-CSF production by
Bhlhe40  /  CD4 þ T cells, these results suggest that Bhlhe40 is
required for GM-CSF production by pathogenic T cells during
neuroinﬂammation.
We also tested an adoptive transfer EAE system in which a WT
TH1-polarized MOG(35–55)-speciﬁc T cell line was transferred to
WT or Bhlhe40  /  recipients42. These T cells produced IFN-g
and GM-CSF, but not IL-17A, upon stimulation (Supplementary
Fig. 2d). When 5 million T cells were transferred, Bhlhe40  / 
mice were protected from EAE, although when 10 million T cells
were transferred, Bhlhe40  /  and WT mice both showed a
similar incidence and severity of EAE (Supplementary Fig. 2e,f).
We speculate that these results are the result of a requirement
for Bhlhe40 in host T cells during the induction of
neuroinﬂammation by low numbers of adoptively transferred
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Figure 1 | Bhlhe40-deﬁcient mice are protected from EAE. (a) Mean clinical scores of EAE in immunized WT (n ¼ 18) or Bhlhe40  /  mice (n ¼ 18). Data
are combined from four independent experiments. Incidence of disease: WT mice 17/18, Bhlhe40  /  mice 2/18. (b) H&E staining of spinal cord
sections from WT and Bhlhe40  /  mice at day 13 after EAE induction. Scale bars: 200 mm in left images, 50 mm in insets. (c) Mean clinical scores of EAE
in BM chimeric mice 13 weeks after bone marrow reconstitution (n ¼ 5 per group). (d) Mean clinical scores of EAE in Rag1  /  mice that received
CD4 þ T cells from either WT or Bhlhe40  /  mice 1 day before immunization (n ¼ 4 per group). For all ﬁgures throughout, error bars show mean±s.e.m.

MOG-speciﬁc T cells. Overall, our results indicate a role for
Bhlhe40 in both immunization-induced and passive EAE.
Bhlhe40 regulates T-cell cytokine production after
immunization. Draining lymph nodes (DLNs) from immunized
Bhlhe40  /  mice had reduced cellularity relative to WT mice
(Supplementary Fig. 3a). Flow cytometry of these DLNs indicated
normal frequencies of lymphoid and myeloid cell populations,
indicating that the decreased cellularity was not due to the
reduction in a particular cell type (Supplementary Fig. 3b).
Similar frequencies of interleukin 2 (IL-2)- and IFN-g-producing
T cells and a modest reduction in the frequency of IL-17A-producing T cells were observed in DLNs from Bhlhe40  /  mice
relative to WT mice in response to stimulation with MOG(35–55)
or concanavalin A (ConA) as measured by ELISPOT assays
(Fig. 3a). Consistent with their decreased IL-17A production, the
frequency of RORgt þ CD4 þ T cells was moderately decreased in
DLNs of Bhlhe40  /  mice (Supplementary Fig. 4a,b). DLNs
from Bhlhe40  /  mice showed a markedly reduced frequency of
MOG(35–55)-speciﬁc GM-CSF-producing T cells relative to WT
mice, and an increased frequency of MOG(35–55)-speciﬁc IL-10producing T cells (Fig. 3b). Intracellular cytokine staining (ICS)
of DLN cells also showed diminished GM-CSF (Supplementary
Fig. 4c,d) and increased IL-10 production (Supplementary
Fig. 4e,f) from Bhlhe40  /  CD4 þ T cells. The defect in GMCSF production by Bhlhe40  /  CD4 þ T cells could not be fully
restored in vitro by culture with IL-1b or IL-23, cytokines that are
reported to promote GM-CSF secretion10–13 (Fig. 3c,d). The
increased IL-10 production by Bhlhe40  /  CD4 þ T cells was
signiﬁcantly augmented by in vitro culture with IL-12 (Fig. 3e,f).
We analysed cytokine production by Bhlhe40  /  T cells in
three additional settings. First, instead of using the self-peptide
MOG(35–55), we immunized mice with the foreign, MHC class
II-restricted peptide of chicken ovalbumin (OVA(323–339)).
Again, Bhlhe40  /  CD4 þ T cells failed to produce GM-CSF

following this immunization, with intact IL-2 and IFN-g
production, and partially decreased IL-17A production
(Supplementary Fig. 4g). Second, we analysed CD4 þ T-cell
cytokine responses in immunized mixed BM chimeric mice.
Bhlhe40  /  T cells showed a T cell-intrinsic defect in GM-CSF
secretion in this setting, with normal IL-17A secretion
(Supplementary Fig. 4h,i). Third, we analysed cytokine responses
in immunized Rag1  /  mice that had received transfers of
puriﬁed WT or Bhlhe40  /  CD4 þ T cells (Supplementary
Fig. 5). Bhlhe40  /  CD4 þ T cells showed reduced GM-CSF
and increased IL-10 production in this setting, with normal
IFN-g production. For unclear reasons, IL-17A secretion by
Bhlhe40  /  CD4 þ T cells appeared decreased in the spleen, but
increased in the DLN in this setting.
gd T cells in the DLNs of immunized Bhlhe40  /  mice also
showed a selective loss of GM-CSF production that could not be
restored by in vitro culture with IL-1b and/or IL-23 (Fig. 3g,h).
Naive splenic gd T cells from non-immunized Bhlhe40  /  mice
were capable of responding to IL-1b, IL-23 and IL-12 (refs 41,43),
as demonstrated by their increased size and granularity, but failed
to produce normal levels of GM-CSF in these cultures
(Supplementary Fig. 6a,b). Overall, these results assessing T-cell
responses in the periphery in combination with our ﬁndings in
the CNS indicate that both CD4 þ and gd T cells require Bhlhe40
to produce GM-CSF.
Bhlhe40 regulates cytokine production by in vitro polarized
TH cells. We tested whether Bhlhe40  /  CD4 þ T cells
responded normally to in vitro activation. Stimulation with platebound anti-CD3 alone or anti-CD3 and anti-CD28 led to normal
IL-2 secretion, reduced GM-CSF secretion and increased
IL-10 secretion by Bhlhe40  /  CD4 þ T cells (Supplementary
Fig. 7a–c). We next examined cytokine production by in vitro
polarized TH cells from WT and Bhlhe40  /  mice. In general,
polarized TH cells from Bhlhe40  /  mice showed normal
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Figure 2 | Diminished neuroinﬂammation in Bhlhe40  /  mice. (a) Flow cytometry of CNS myeloid cells from WT and Bhlhe40  /  mice (n ¼ 3 per
group) on day 16 after immunization. (b) Percentage of MHC class II þ microglia and inﬁltrating myeloid cells. (c–e) Flow cytometry of CD4 þ T cells
in the CNS of WT and Bhlhe40  /  mice (n ¼ 3 per group) on day 16 after immunization. (c) CD4 þ T cell number. (d) Representative ICS for the
indicated cytokines. (e) Frequency of CD4 þ T cells secreting each of the indicated eight possible combinations of GM-CSF, IL-17A and IFN-g. (f,g) Flow
cytometry of gd T cells in the CNS of WT and Bhlhe40  /  mice (n ¼ 3 per group) on day 14 after immunization. (f) Representative ICS for IFN-g,
IL-17A and GM- CSF. (g) Frequency of gd T cells secreting IFN-g, IL-17A or GM-CSF.

production of their signature cytokines, although Bhlhe40  / 
TH1 cells showed a B40% decrease in IFN-g production, consistent with a previous report39 (Fig. 4a,b). Consistent with these
cytokine results, we found decreased expression of the
transcription factor T-bet in Bhlhe40  /  TH1 cells, with nearly
normal expression of Gata-3 and RORgt in Bhlhe40  /  TH2 and
TH17 cells, respectively (Supplementary Fig. 7e).
GM-CSF production varied between WT TH1, TH2 and TH17
cells, with the least production of GM-CSF found in TH1 cultures
(Fig. 4a–c), consistent with an earlier report10. Bhlhe40  / 
T cells showed markedly reduced production of GM-CSF under
all conditions of differentiation (Fig. 4a–c). This lack of GM-CSF
4

production by Bhlhe40  /  T cells was also seen in TH17 cultures
that utilized TGF-b3 in place of TGF-b1 (ref. 26) (Supplementary
Fig. 7f).
Bhlhe40  /  TH1 and TH17 cells showed increased IL-10
production relative to WT cells, while WT and Bhlhe40  /  TH2
cells showed similar, high-level IL-10 production (Fig. 4a,b). The
increased IL-10 production in Bhlhe40  /  TH1 cells came
largely from IFN-g þ cells, while in TH17 cultures it came from
both IL-17A þ and IL-17A  populations (Fig. 4d). We further
tested whether the increased IL-10 production by Bhlhe40  / 
TH cells could contribute to their diminished GM-CSF production. Co-culture of congenically marked WT and Bhlhe40  / 
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TH cells under non-polarizing conditions showed that increased
IL-10 secretion and decreased GM-CSF secretion were both cellintrinsic properties of Bhlhe40  /  TH cells (Fig. 4e).
We tested whether abnormal GM-CSF and IL-10 production
by Bhlhe40  /  CD4 þ T cells could be restored by the
reintroduction of Bhlhe40. Retrovirally transduced Bhlhe40  / 
TH1 and TH17 cells overexpressing Bhlhe40 produced increased
levels of GM-CSF and decreased levels of IL-10 compared with
non-transduced Bhlhe40  /  T cells or Bhlhe40  /  T cells
transduced by an empty retrovirus (Supplementary Fig. 8).
Overexpressing Bhlhe40 modestly increased GM-CSF and
decreased IL-10 production by WT TH17 cells, but had little
effect on WT TH1 cells.
Molecular analysis of Bhlhe40-regulated target genes.
We performed expression microarray analysis on WT and
Bhlhe40  /  CD4 þ T cells cultured in TH1, TH2 and TH17
conditions and validated these results by quantitative RT-PCR for
selected transcripts (Fig. 5). This analysis conﬁrmed that
Bhlhe40  /  T cells were able to acquire characteristics largely
reﬂective of normal TH1, TH2 or TH17 differentiation, including
their expression of signature cytokines and transcription factors
(Fig. 5a,d). However, a common set of genes was affected by the
loss of Bhlhe40 across two or more TH lineages (Fig. 5b,c and e),
including reduced expression of Csf2, Il3, Il1a, Ccl1, Iﬁtm3 and
Ptgs2. Notably, expression levels of Il10, Ikzf3 (Aiolos) and Xcl1
were increased in Bhlhe40  /  T cells. We conﬁrmed reduced
secretion of IL-3 by Bhlhe40  /  CD4 þ T cells following
stimulation with anti-CD3 alone or anti-CD3 and anti-CD28
(Supplementary Fig. 7d).
To examine whether the Il3/Csf2 and Il10 loci were directly
bound by Bhlhe40, we performed an analysis of Bhlhe40 ChIPSeq data generated from CH12 cells by the Mouse Encyclopedia
of DNA Elements (ENCODE) Consortium44. RNA sequencing
(RNA-Seq) performed on this B-cell lymphoma line by the same
Consortium showed these cells to express Bhlhe40, Il3, Csf2 and
Il10. Within the Il3/Csf2 locus, Bhlhe40 bound multiple sites,
including a previously identiﬁed distal enhancer located B30 kb
downstream of Csf2 that regulates the expression of both cytokine
genes in this locus45 (Supplementary Fig. 9a). Within the Il10
locus, Bhlhe40 also bound multiple sites, including two known
regulatory elements46,47 (Supplementary Fig. 9b). In both loci,
many regions bound by Bhlhe40 were also bound by the general
transcriptional regulators p300 (refs 48,49) and BRG1 (ref. 45)
and the TH cell subset-speciﬁc transcription factors T-bet (ref. 50)
and RORgt (ref. 49). Bhlhe40 is likely one of many transcriptional
regulators present at these regions working in concert to control
gene expression.
IL-10R blockade renders Bhlhe40  /  mice susceptible to EAE.
As our expression microarray experiments demonstrate that
Bhlhe40 deﬁciency leads to the dysregulation of hundreds of
genes in polarized TH cells, we expect that the summation of these
changes in gene expression underlies the T cell-intrinsic
requirement for Bhlhe40 in T-cell encephalitogenicity. Nevertheless, we sought to test whether the administration of exogenous GM-CSF could render Bhlhe40  /  mice susceptible to EAE.
In two individual experiments, Bhlhe40  /  mice treated daily
with either 10 or 100 ng per day recombinant murine GM-CSF
intraperitoneally beginning on the day of immunization did not
develop clinical EAE (n ¼ 3–5 mice per experiment). In both of
these experiments, control WT mice experienced a typical course
of EAE, indicating successful immunization. Systemic GM-CSF
treatment at a dose of 10 ng per day was reported to replace
endogenous GM-CSF in Csf2  /  mice, such that these mice

developed EAE when GM-CSF was administered after immunization51. Therefore, we take our results to indicate that
Bhlhe40  /  mice resist EAE for reasons beyond just their
defective production of GM-CSF by T cells.
We also tested whether blockade of IL-10 signalling could
affect the development of EAE in Bhlhe40  /  mice. Groups of
WT or Bhlhe40  /  mice were treated biweekly with control rat
IgG or anti-IL-10R blocking antibody, beginning 1 day prior to
immunization and continuing throughout the course of the
experiment. Anti-IL-10R antibody treatment of immunized WT
mice led to the high incidence of early morbidity and a shock-like
syndrome, characterized by rufﬂed fur, weight loss and a hunched
posture, with rapid death prior to the onset of clinical EAE
(Fig. 6a). This unexpected mortality, which we attribute to acute
IL-10R blockade in the setting of a strong immune stimulus, was
not apparent in immunized WT mice treated with control
antibody, which experienced a typical course of EAE (Fig. 6b and
Table 1). Immunized Bhlhe40  /  mice treated with anti-IL-10R
antibody experienced only infrequent early morbidity. Those
WT mice treated with anti-IL-10R antibody that did not succumb
to an early death developed very severe EAE. Immunized
Bhlhe40  /  mice treated with control antibody resisted EAE,
while nearly half of all Bhlhe40  /  mice treated with anti-IL10R antibody developed severe clinical EAE, like that of control
antibody-treated WT mice. Overall, these results reveal that the
pathogenicity of Bhlhe40  /  autoreactive T cells is regulated by
IL-10.
Discussion
Here we have shown that Bhlhe40  /  mice are protected from
immunization-induced autoimmune neuroinﬂammation. TH cells
have a cell-intrinsic requirement for Bhlhe40 during encephalomyelitis, and in these cells Bhlhe40 transcriptionally regulates the
production of GM-CSF and IL-10. In vivo blockade of IL-10R
allows immunized Bhlhe40  /  mice to develop EAE, indicating
the important role of this cytokine in regulating autoreactive
T-cell pathogenicity.
Bhlhe40  /  mice were also protected from adoptively
transferred EAE using an encephalitogenic TH1 cell line, but
only when a low number of pathogenic T cells were transferred
(Supplementary Fig. 2e). In this system, cytokine-producing host
TH cells inﬁltrate the CNS and participate in regulating
neuroinﬂammation42. Large numbers of adoptively transferred,
autoreactive WT TH1 cells were capable of overcoming a
requirement for Bhlhe40 in host cells (Supplementary Fig. 2f).
Overall, these results are reminiscent of experiments in which low
numbers of an encephalitogenic TH1 cell line were unable to
induce disease in IL-17A-deﬁcient mice, but in which higher cell
numbers could initiate neuroinﬂammation42. We favour a model
in which the explanation for our adoptive transfer results stems
from a requirement for Bhlhe40 in host TH and gd T cells,
although it remains a possibility that Bhlhe40 also functions in
non-T cells during adoptively transferred EAE.
The characteristics that deﬁne pathogenic TH cells in EAE have
been a subject of recent debate24–26. Neither IFN-g nor IL-17, the
signature cytokines of TH1 and TH17 cells, are required for
the development of EAE4,5, yet in vitro derived TH1 and
TH17 cells speciﬁc for myelin antigens both can induce
encephalomyelitis8,52. These seemingly conﬂicting observations
have been reconciled by the recent ﬁnding that GM-CSF,
produced by both TH1 and TH17 cells, serves a non-redundant
pro-inﬂammatory role in EAE development8–12. Control of Csf2
expression involves AP-1, NFAT, Runx1, NF-kB, histone
acetylation and BRG1 recruitment14–19,45. c-Rel- and NF-kB1deﬁcient T cells produce less GM-CSF, but these factors may be
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non-selective in their impact on cytokine production17,18. Malt1,
a protease regulating the NF-kB pathway, was reported to be
required for GM-CSF production by TH17 cells, but not TH1
cells53, implying that the pathways that control GM-CSF
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abrogated in Bhlhe40  /  TH2 cells. Similarly, our observation
that Bhlhe40  /  mice can infrequently develop clinical EAE
with some T-cell production of GM-CSF (Supplementary Fig. 2a)
in the CNS indicates that Bhlhe40 is not absolutely required for
Csf2 expression in T cells. Bhlhe41 (also known as Dec2, Sharp1
or Bhlhb3), the closest homologue to Bhlhe40, is expressed most
highly in TH2 cells among activated TH-cell subsets40,54, and
perhaps this factor can substitute for Bhlhe40 in some settings in
the regulation of Csf2 transcription.
The role of RORgt in GM-CSF production by CD4 þ T cells is
controversial10–12. One study found that Rorc  /  CD4 þ T cells
activated in the presence of anti-IFN-g- and anti-IL-12neutralizing antibodies produced less GM-CSF than WT CD4 þ
T cells, but Rorc  /  TH1 and TH17 cells produced normal or
even greater GM-CSF than WT T cells10. These investigators
found that retroviral RORgt overexpression increased GM-CSF
production, so despite these incongruous results, they suggested
that RORgt drives GM-CSF production. A second study also
showed that Rorc  /  TH17 cells produced an increased amount
of GM-CSF relative to WT TH17 cells11, leading this group to
suggest that RORgt is not required for GM-CSF production. We
observed normal Rorc expression in Bhlhe40  /  TH17 cells in
our microarrays (Fig. 5a), and speculate that Bhlhe40 directly
regulates Csf2 expression.
The recently described molecular signatures of pathogenic
versus non-pathogenic TH17 cells26 includes four genes that we
ﬁnd to be selectively regulated by Bhlhe40 (Csf2 and Il3 for
pathogenic TH17 cells; Il10 and Ikzf3 for non-pathogenic TH17
cells) (Fig. 5). Given these data, we believe that Bhlhe40 serves as
a transcription factor that shapes the encephalitogenicity of TH17
cells. Considering IL-10 production in particular, we ﬁnd the
largest difference between WT and Bhlhe40  /  TH cells to be in
TH1 cultures or in cells from immunized mice cultured with
IL-12. This type of IL-10 production by TH1 cells has been
reported to involve signals through ERK, STAT4 and c-Maf33.
Our data point to a cell-intrinsic role for Bhlhe40 in regulating
IL-10 production in T cells, and we speculate that Bhlhe40 serves
as a direct negative regulator of Il10. Bhlhe40 could be acting in
TH cells in some cases as a transcriptional activator and in others
as a transcriptional repressor on different direct target genes,
perhaps based on its interactions with other transcription factors.
Examples exist for both activating and repressive functions of
Bhlhe40 (refs 55,56). It also remains possible that some genes
whose expression is abnormal in Bhlhe40  /  TH cells are
indirect targets of Bhlhe40.
Supporting the importance of IL-10 in EAE pathogenesis, we
found that nearly half of all Bhlhe40  /  mice treated with an
anti-IL-10R blocking antibody developed EAE. Although IL-10deﬁcient mice are known to develop more severe EAE than WT
mice28–30, they have not been reported to exhibit early mortality

prior to the onset of encephalomyelitis. We speculate that the
sudden inhibition of IL-10 signalling by anti-IL-10R antibody in
our experiments is fundamentally different than the lifelong
absence of this signalling, such that antibody-mediated blockade
resulted in a pro-inﬂammatory cytokine-driven shock-like
syndrome. Antibody-treated Bhlhe40  /  mice were largely
protected from this syndrome, implying that pro-inﬂammatory
cytokines in these mice, perhaps including GM-CSF, were
produced at lower levels. Interestingly, some Bhlhe40  /  mice
were fully protected from EAE even in the setting of IL-10R
blockade, and we speculate that this was also due to their
decreased levels of pro-inﬂammatory cytokines. Nevertheless,
our results support the notion that Bhlhe40  /  TH cells
can be encephalitogenic in the setting of IL-10R blockade.
Further experiments will be performed to determine whether
Bhlhe40  /  TH cells are themselves the critical source of IL-10
preventing autoimmunity in these mice.
While we were preparing this manuscript, a separate study also
identiﬁed Bhlhe40 as a transcription factor required for
autoreactive CD4 þ T-cell responses using the EAE system57.
Martı́nez-Llordella et al.57 identiﬁed Bhlhe40 as a gene whose
expression was induced in activated CD4 þ T cells in a CD28dependent manner. These authors found Bhlhe40-deﬁcient mice
(a separately generated line than was used in our study58) to be
resistant to the induction of EAE, and found decreased CD4 þ
T cell production of several cytokines, including GM-CSF. Both
our study and theirs found decreased IL-17A responses in
immunized Bhlhe40  /  mice, with both identifying this defect
as cell-extrinsic based on immunization experiments in mixed
bone marrow chimeras. Our in vitro experiments showing normal
Il17a transcript and IL-17A production by Bhlhe40  /  TH17
cells also suggest no direct role for Bhlhe40 in controlling this
cytokine.
There are some key differences between our study and the
work of Martı́nez-Llordella et al.57 They observed MOG(35–55)speciﬁc CD4 þ T-cell responses in Bhlhe40  /  mice to be only
slightly reduced in frequency at day 7 after immunization as
determined by tetramer staining, but to be completely absent
when assessed with a proliferation assay or by ELISAs for IL-17A,
IFN-g and GM-CSF. In our assessment of CD4 þ T-cell priming
by ELISPOT assays using DLN cells at day 7 after immunization,
we found essentially intact IL-2 and IFN-g responses, partially
decreased IL-17A responses and absent GM-CSF responses
(Fig. 3a,b). We speculate that technical differences in the assay
formats, cell culture densities or assay times could explain these
discrepancies. An additional difference between our study and
that of Martı́nez-Llordella et al.57 is that we found normal
IL-2 production after in vitro stimulation of Bhlhe40  /  CD4 þ
T cells (Supplementary Fig. 7a), while they saw a B50%
reduction in IL-2 secretion. Our results are consistent with

Figure 3 | T cells require Bhlhe40 for normal cytokine production after immunization. (a,b) ELISPOT assays for the quantitation of cells secreting
(a) IL-2, IFN-g, and IL-17A or (b) GM-CSF and IL-10 performed on DLN cells 7 days after immunization of WT and Bhlhe40  /  mice. Data for IL-2, IFN-g,
IL-17A and GM-CSF are combined from three independent experiments (n ¼ 9 mice per group). Data for IL-10 is from one representative experiment
of two (n ¼ 4 mice per group). (c,e) DLN cells from immunized WT and Bhlhe40  /  mice (n ¼ 14 per group) were cultured with or without MOG(35–55)
and with or without IL-1b, IL-23 and/or IL-12 as indicated. (c) GM-CSF or (e) IL-10 was measured in the supernatant at day 4. Data are combined
from ﬁve independent experiments. Cells from all mice were not used in all conditions in each of the four experiments. (d) DLN cells from immunized WT
and Bhlhe40  /  mice were cultured with MOG(35–55) with or without IL-1b for 4 days, followed by ICS. Representative plots are gated on CD4 þ
T cells. (f) DLN cells from immunized WT and Bhlhe40  /  mice were cultured with MOG(35–55) with or without IL-12 for 4 days, followed by ICS.
Representative plots are gated on CD4 þ T cells. (g) Frequencies of GM-CSF þ and IL-17A þ gd T cells in DLNs 7 days after immunization of WT and
Bhlhe40  /  mice (n ¼ 3 per group) as determined by ICS. (h) DLN cells from immunized WT and Bhlhe40  /  mice were cultured with or
without MOG(35–55) and with or without IL-1b and/or IL-23 as indicated for 4 days. Cells were stimulated with PMA/ionomycin in the presence
of brefeldin A for 4 h and then analysed for IL-17A and GM-CSF by intracellular staining (that is, our normal ICS protocol). Representative plots are gated
on gd T cells.
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Figure 4 | TH cells require Bhlhe40 for normal cytokine production in vitro. (a–d) CD4 þ T cells from WT and Bhlhe40  /  mice (n ¼ 3 per group) were
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those of Miyazaki et al.38 who reported normal IL-2 secretion by
Bhlhe40  /  CD4 þ T cells, and we again speculate that
differences in cell culture conditions may explain these
discrepancies. Finally, our expression microarrays and
phenotypic analysis of polarized Bhlhe40  /  TH cells
identiﬁed increased transcription and secretion of IL-10 by
these cells compared with WT TH cells. Il10 was not identiﬁed as
being differentially expressed in the transcriptional analysis
8

performed by Martı́nez-Llordella et al.57, although we
speculate that this may be related to their analysis of naive T
cells activated under non-polarizing conditions at early time
points (4 and 24 h).
In conclusion, we have demonstrated that Bhlhe40 is required
for the encephalitogenicity of CD4 þ T cells, likely through its
regulation of GM-CSF and IL-10 production. Bhlhe40 is also
required for gd T-cell production of GM-CSF. Bhlhe40 controls
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Figure 5 | Transcriptional analysis of Bhlhe40-deﬁcient TH cells. (a) Heat map of gene expression for selected TH1, TH2 and TH17 lineage-speciﬁc genes
in polarized WT and Bhlhe40  /  TH cells. (b) Pairwise comparison of WT and Bhlhe40  /  TH1, TH2 and TH17 cells. Probes that are overexpressed
Z2-fold in the indicated populations are shown in red or blue. Numbers in corners indicate the total number of probes meeting these conditions. Probes for
selected relevant genes are shown in green. Coefﬁcients of determination (R2) are indicated for each comparison. (c) Venn diagrams showing the
overlap of probes differentially expressed by WT and KO TH cell lineages. Numbers in regions indicate the number of probes with greater than or equal to a
twofold difference in expression (WT4KO or WToKO). (d) Quantitative RT-PCR analysis of Ifng, Il4 and Il17a expression in WT and Bhlhe40  /  TH1, TH2
and TH17 cells (n ¼ 3 per group). (e) Quantitative RT-PCR analysis of the expression of the indicated nine genes in WT and Bhlhe40  /  TH1, TH2
and TH17 cells (n ¼ 3 per group).

these cytokines transcriptionally, but further investigation will be
required to understand the molecular details of this regulation.
Moreover, the question of whether regulation of these cytokines
by Bhlhe40 in T cells inﬂuences pathogenesis in other
autoimmune or infectious diseases is intriguing. The role of

GM-CSF in autoimmune disease has prompted clinical interest in
therapeutics to target this cytokine in rheumatoid arthritis and
multiple sclerosis59. Bhlhe40, or pathways that regulate its
expression or function, could also represent therapeutic targets
in human autoimmunity.
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Figure 6 | IL-10R blockade renders Bhlhe40  /  mice susceptible to EAE. (a) Survival of WT or Bhlhe40  /  mice after EAE induction and biweekly
treatment with control rat IgG or anti-IL-10R antibody. Data are combined from three independent experiments. (b) Mean clinical scores of EAE
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experiments. Error bars are not shown for clarity. All s.e.m. values were r1.

Table 1 | Clinical EAE data in WT and Bhlhe40  /  mice
treated with rat IgG or anti-IL-10R antibody.

WT þ rat IgG
Bhlhe40  /  þ rat IgG
WT þ anti-IL-10R
Bhlhe40  /  þ anti-IL-10R

Day of
onset*
11±0.4
9.0
10±1.0
12±1.5

Incidence
100% (7/7)
11.1% (1/9)
100% (2/2)
44.4% (4/9)

Maximum
score*
3.43±0.20
2.00
4.00±0.00
3.25±0.25

*Mean±s.e.m. of diseased mice.

Methods
Mice. C57BL/6 (Taconic), B6.SJL (Taconic), B6.PL-Thy1a/CyJ (Jackson),

Rag1  /  (on a C57BL/6 background, Jackson) and Bhlhe40  /  mice39
(backcrossed 10 generations to the C57BL/6 background) were maintained in our
SPF facility. Experiments were performed with mice of either sex (groups were sexmatched within individual experiments) at 8–24 weeks of age. No Bhlhe40  / 
mice on the C57BL/6 background displayed lymphoproliferative disease in our
colony throughout this age range, in keeping with a previous report of C57BL/6
Bhlhe40  /  mice38. Flow cytometry of splenocytes and bone marrow from
Bhlhe40  /  mice in our colony at the ages used in these experiments showed
normal leukocyte populations (Supplementary Fig. 10). All animal experiments
were approved by the Animal Studies Committee of Washington University.
Bone marrow transplantation and TH cell transfers. Bone marrow cells were
collected from femurs and tibias of donor mice, and 10–20 million cells were
injected intravenously into recipient mice following irradiation (1,200 rads). Mixed
chimeras were prepared by mixing donor bone marrow cells at a 1:1 ratio before
injection. Mice were used in experiments 13–16 weeks following transplantation.
For cell transfers, total CD4 þ T cells were magnetically puriﬁed from donor
splenocytes (Invitrogen Dynabeads FlowComp Mouse CD4 kit, typical purity
B90–95%). CD4 þ T cells (7 to 10 million) were injected intravenously into
Rag1  /  mice 1 day prior to the induction of EAE or immunization for the
assessment of T-cell responses.
Induction of EAE and immunizations. For active EAE induction, mice were
immunized subcutaneously with 100 mg MOG(35–55) (C S Bio Co.) emulsiﬁed in
CFA (made with 5 mg ml  heat-killed Mycobacterium tuberculosis H37Ra (BD
Difco) in incomplete Freund’s adjuvant (BD Difco)). Pertussis toxin (List Biological
Laboratories) was injected intraperitoneally (300 ng) on days 0 and 2. Mice were
observed for signs of EAE and graded on a standard 0–5 scale as described11. In
some experiments, mice were treated daily with recombinant murine GM-CSF
(Peprotech) at a dose of 10 ng per day or 100 ng per day intraperitoneally,
beginning on the day of immunization and continuing throughout the course of
the experiment. In some experiments, mice were treated with control rat IgG
(Sigma) or anti-IL-10R monoclonal antibody (clone 1B1.3A, BioXcell)60. Mice were
given 250 mg of antibody intraperitoneally two times per week, beginning 1 day
prior to immunization. For histology experiments, spinal cords were dissected,
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ﬁxed in formalin, embedded in parafﬁn, sectioned and stained with hematoxylin
and eosin (H&E).
For adoptively transferred EAE, MOG(35–55)-speciﬁc TH1 cell lines were
generated by culturing CD4 þ T cells from MOG(35–55)-immunized CD90.1
congenic B6.PL-Thy1a/CyJ mice with MOG(35–55), irradiated C57BL/6 splenocytes, IL-2 and IL-12 for two or four rounds of stimulation42. Four days after the
last stimulation, 5–10 million live T cells were intravenously transferred to
recipient mice.
For analysis of T-cell responses in DLNs, mice were immunized in hind
footpads with 10 nanomoles MOG(35–55) or OVA(323–339) emulsiﬁed in CFA.
Popliteal lymph nodes were collected on day 7.
Cell preparation. DLNs from immunized mice were digested with 250 mg ml  1
collagenase B (Roche) and 30 U ml  1 Dnase I (EMD) for 40–60 min at 37 °C with
stirring in Iscove’s modiﬁed Dulbecco’s media containing 10% FCS, L-glutamine,
sodium pyruvate, non-essential amino acids, penicillin/streptomycin and 2-mercaptoethanol (cIMDM). EDTA (5 mM ﬁnal) was added and cells were incubated
on ice for 5 min. Cells were passed through a 70-mm strainer before cell counting
with trypan blue. Spleens were mashed between frosted glass slides and made into
a single-cell suspension. Red blood cells were lysed with ACK lysis buffer. Cells
were passed through a 70-mm strainer before cell counting with acetic acid.
Brains and spinal cords were removed following perfusion with 30 ml PBS via
cardiac puncture of the left ventricle. Organs were minced and digested with
500 mg ml  1 Type I collagenase (Sigma) and 10 mg ml  1 DNAse I (Sigma) in the
presence of 0.1 mg ml  1 TLCK trypsin inhibitor (Sigma) and 10 mM Hepes (pH
7.4) in HBSS at room temperature for 1 h. Following centrifugation, cells were
resuspended in 70% Percoll (Sigma) in HBSS and additional 37% and 30% layers
were added above the cells. Gradients were centrifuged for 30 min at 1,200 g. The
30% Percoll layer containing debris was discarded, and the cells from the 37% layer
were collected and washed in HBSS before stimulation or ﬂow cytometry.
Cell culture. DLN cells from MOG(35–55)-immunized mice were cultured in
cIMDM and stimulated with 10 mM MOG(35–55) for 4 days before supernatants
were collected for ELISAs or before ICS. In some cases, IL-1b (10 ng ml  1, BioLegend), IL-23 (20 ng ml  1, BioLegend) or IL-12 (2 ng ml  1, BioLegend) was
added to the culture at set-up.
Splenocytes or magnetically puriﬁed total splenic CD4 þ T cells (Invitrogen
Dynabeads FlowComp Mouse CD4 kit) from untreated mice cultured in cIMDM
were stimulated with plate-bound anti-CD3 antibody (10 mg ml  1, clone 1452C11, BioLegend) with or without plate-bound anti-CD28 antibody for 48–72 h
(5 mg ml  1, clone 37.51, BioLegend). Supernatants were collected for ELISAs or
ICS was performed on cells. In some experiments, splenocytes were cultured
for 3 days with IL-1b and/or IL-23 without TCR stimulation. ICS was subsequently
performed on these cells, gating on gd T cells.
For TH cell polarization, magnetically puriﬁed total CD4 þ T cells (Invitrogen
Dynabeads FlowComp Mouse CD4 kit) or naive CD4 þ T cells (Stemcell
Technologies Easysep Mouse Naive CD4 þ T Cell Isolation kit, typical purity
B90–96%) were cultured in cIMDM with plate-bound anti-CD3 and anti-CD28
antibodies in the presence of cytokines (BioLegend except TGF-b3) and
neutralizing antibodies (BioLegend except anti-IL-12) as follows. TH1 conditions:
IFN-g (200 ng ml  1), IL-12 (2 ng ml  1), anti-IL-4 (5 mg ml  1, clone 11B11). TH2
conditions: IL-4 (10 ng ml  1), anti-IFN-g (5 mg ml  1, clone XMG1.2 or clone
H22), anti-IL-12 (10 mg ml  1, clone Tosh, a gift from Emil Unanue, Washington
University). TH17 conditions: TGF-b1 (2 ng ml  1) or TGF-b3 (2 ng ml  1)
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(Miltenyi), IL-6 (25 ng ml  1), IL-1b (10 ng ml  1), IL-23 (10 ng ml  1), anti-IL-4
and anti-IFN-g. Cells were split at day 3, and on days 4–5 cells were either used for
ICS or stimulated for 24 h with plate-bound anti-CD3 and anti-CD28 for
assessment of cytokine secretion by ELISA.
ELISPOT and ELISA assays. ELISPOT assays were performed on Mutiscreen
Filter Plates (Millipore). DLN cells from immunized mice were plated at
5  105–1  106 cells per well in cIMDM and stimulated with 10 mM peptide or
1 mg ml  1 ConA overnight at 37°C. IL-2, IFN-g and IL-10 ELISPOT antibody
pairs were from BD Bioscience. IL-17 and GM-CSF ELISPOT antibody pairs and
streptavidin-alkaline phosphatase were from BioLegend. Plates were developed
with NBT/BCIP substrate (Roche) and spots were counted on an Immunospot
counter (Cellular Technology Ltd.). ELISA assays were performed on Nunc
Maxisorp plates using the same antibody pairs as above but were developed with
streptavidin-HRP (BioLegend) and TMB substrate (BioLegend). Standard curves
for these ELISAs were generated with puriﬁed cytokines. The Mouse IL-3 ELISA
MAX kit was used to measure IL-3 (BioLegend).
Flow cytometry. All antibodies were used at a dilution of 1/200 except where
noted. Streptavidin conjugates were used at a dilution of 1/400. The following antimouse antibodies were from BioLegend: FITC, APC or biotin anti-CD3e (1452C11), PB anti-CD4 (RM4-5), APC-Cy7 or PerCP-Cy5.5 anti-CD8a (53-6.7), APC
or biotin anti-TCR gd (GL3), FITC anti-CD25 (PC61), PB anti-CD44 (IM7), FITC
anti-B220 (RA3-6B2), FITC anti-CD45.1 (A20), APC or biotin anti-CD45.2 (104),
PerCP-Cy5.5 anti-Siglec H (551), FITC anti-Ly6C (HK1.4), PE anti-Ly6G (1A8),
PE-Cy7 anti-CD11b (M1/70), APC-Cy7 anti-CD11c (N418), PB anti-I-A/I-E (M5/
114.15.2, used at 1/500), PE-Cy7 anti-IFN-g (XMG1.2), PerCP-Cy5.5 anti-IL-17A
(TC11-18H10.1), PE anti-GM-CSF (MP1-22E9), PE anti-KLH (RTK2758, isotype
rat IgG2a, k), APC or biotin anti-IL-10 (JES5-16E3) and streptavidin-APC. The
following anti-mouse antibodies were from BD Biosciences: V450 anti-CD4 (RM45) and V500 anti-B220 (RA3-6B2). APC anti-CD62L (MEL-14), PE anti-CD25
(PC61.5), APC-e780 anti-CD45 (30-F11, used at 1/600), PE anti-Foxp3 (FJK-16s),
eFluor660 anti-T-bet (eBio4B10), PerCP-eFluor710 anti-Gata-3 (TWAJ), APC
anti-RORgt (AFKJS-9) and streptavidin-APC-e780 were from eBioscience.
For ICS, cells were stimulated with PMA (50 ng ml  1, Enzo Life Sciences) and
ionomycin (1 nM, Enzo Life Sciences) in the presence of brefeldin A (1 mg ml  1,
Enzo Life Sciences) for 4–5 hours. Surface staining was performed in FACS buffer
(0.5% BSA, 2 mM EDTA, 0.02% sodium azide in PBS) in the presence of Fc
receptor blocking antibody (clone 93, BioLegend) for 20 min at 4 °C followed by
streptavidin staining if necessary. Cells were ﬁxed in 4% paraformaldehyde
(Electron Microscopy Sciences) for 20 min at room temperature followed by
permeabilization (0.1% BSA, 0.5% saponin in PBS) or with the BD Cytoﬁx/
Cytoperm Fixation and Permeabilization Kit. Cytokine staining was performed in
permeabilization buffer for 20 min at 4 °C. Staining for intracellular Foxp3, T-bet,
Gata-3 and RORgt was performed in the Foxp3/Transcription Factor Staining
Buffer Set (eBioscience). Flow cytometry was performed on a FACSCanto II (BD
Bioscience) and data was analysed with FlowJo (Tree Star Inc.).
For microarray experiments, naive CD4 þ T cells (CD4 þ B220  CD25 
CD44loCD62Lhi) were puriﬁed (98% purity) by cell sorting on a FACSAria II (BD
Biosciences) after B-cell depletion using anti-B220 magnetic beads (Invitrogen).
Expression microarrays. Naive CD4 þ T cells were cultured in TH0, TH1, TH2 or
TH17 conditions for 4 days and stimulated for 4 h with PMA and ionomycin before
total RNA was isolated (EZNA MicroElute Total RNA Kit, Omega Bio-Tek). RNA
was ampliﬁed (Ovation PicoSL WTA System V2, Nugen), labelled (Encore Biotin
Module, Nugen), fragmented and hybridized to Affymetrix Gene 1.0ST arrays.
Array data were imported into Arraystar 5 software (DNAstar) and then normalized using the robust multi-array analysis method with quantile normalization.
Probesets were curated according to a validated gene annotation, and only these
probesets were utilized in subsequent analyses. Correlation analysis was performed
using Arraystar 5. Heat maps were generated using GENE-E software (Broad
Institute, http://www.broadinstitute.org/cancer/software/GENE-E/). For analysis of
GSE14308 (ref. 61), which was performed on Affymetrix Mouse Genome 430 2.0
arrays, we also used the robust multi-array analysis method with quantile
normalization using Arraystar 5 software.
Quantitative RT-PCR. Magnetically puriﬁed total splenic CD4 þ T cells (Invitrogen Dynabeads FlowComp Mouse CD4 kit) were cultured in TH1, TH2 or TH17
conditions for 4 days and stimulated for 4 h with plate-bound anti-CD3 and antiCD28 before total RNA was isolated (EZNA MicroElute Total RNA Kit, Omega
Bio-Tek). cDNA was synthesized (High Capacity RNA-to-cDNA Kit, Invitrogen)
and quantitative real-time PCR was performed according to the manufacturer’s
instructions with Power SYBR Green PCR Master Mix (Applied Biosystems) on a
StepOnePlus Real-Time PCR system (Applied Biosystems). Expression of genes
was determined relative to Hprt by the DCT method.
The following primers were used for quantitative RT-PCR. Ccl1, forward 50 -GG
CTGCCGTGTGGATACAG-30 , reverse 50 -AGGTGATTTTGAACCCACGTTT-30 ;
Csf2, forward 50 -GCCATCAAAGAAGCCCTGAA-30 , reverse 50 -GCGGGTCTG
CACACATGTTA-30 ; Hprt, forward 50 -TCAGTCAACGGGGGACATAAA-30 ,

reverse 50 -GGGGCTGTACTGCTTAACCAG-30 ; Iﬁtm3, forward 50 -CCCCCAAA
CTACGAAAGAATCA-30 , reverse 50 - ACCATCTTCCGATCCCTAGAC-30 ; Ifng,
forward 50 -GGATGCATTCATGAGTATTGC-30 , reverse 50 -CCTTTTCCGCTTCC
TGAGG-30 ; Ikzf3, forward 50 -CTGAATGACTACAGCTTGCCC-30 , reverse
50 -GCTCCGGCTTCATAATGTTCT-30 ; Il1a, forward 50 - CGAAGACTACAGTTC
TGCCATT-30 , reverse 50 -GACGTTTCAGAGGTTCTCAGAG-30 ; Il3, forward
50 -GGGATACCCACCGTTTAACCA-30 , reverse 50 -AGGTTTACTCTCCGAAAG
CTCTT-30 ; Il4, forward 50 -ATCATCGGCATTTTGAACGAGG-30 , reverse 50 - TG
CAGCTCCATGAGAACACTA-30 ; Il10, forward 50 -AGCCTTATCGGAAATGA
TCCAGT-30 , reverse 50 -GGCCTTGTAGACACCTTGGT-30 ; Il17a, forward
50 -TTTAACTCCCTTGGCGCAAAA-30 , reverse 50 -CTTTCCCTCCGCATTGAC
AC-30 ; Ptgs2, forward 50 -TGCACTATGGTTACAAAAGCTGG-30 , reverse 50 -TCA
GGAAGCTCCTTATTTCCCTT-30 ; Xcl1, forward 50 -TAGCTGTGTGAACTTACA
AACCC-30 , reverse 50 -ACAGTCTTGATCGCTGCTTTC-30 .
ChIP-Seq data analysis. Bhlhe40 ChIP-Seq data and RNA-Seq data performed by
ENCODE/Stanford/Yale using CH12 cells were directly viewed in the University of
California Santa Cruz (UCSC) Genome Browser on the NCBI37/mm9 mouse
genome assembly. Discriminative DNA Motif Discovery (DREME) software
(ref. 62) was used as part of the online version of MEME-ChIP (http://meme.nbcr.
net/meme/cgi-bin/meme-chip.cgi)63 to validate that Bhlhe40 ChIP-Seq data
identiﬁed the expected consensus motif for Bhlhe40 (CACGTG)64 with a
signiﬁcant E-value (4.8  10  1,391).
Raw data for the following ChIP-Seq data sets were downloaded from the Gene
Expression Omnibus of the NCBI: GSE40463 (p300 in TH1 and TH2 cells)48,
GSE33802 (T-bet in TH1 cells)50, GSE20898 (Gata-3 in TH2 cells)65, GSE40918
(RORgt and p300 in TH17 cells)49 and GSE23719 (BRG1 in stimulated TH1, TH2,
and TH17 cells)66. Each of these data sets was put through the following pipeline of
analysis within Galaxy (http://usegalaxy.org/)67–69: FASTQ ﬁles were groomed,
mapped to the NCBI37/mm9 mouse genome assembly using Bowtie, converted
from SAM to BAM ﬁles and peak called using MACS software. Tracks were then
viewed in the UCSC Genome Browser.
Cloning of Bhlhe40 and retroviral transduction. The murine Bhlhe40 full-length
cDNA (coding for amino acids 2–411) was cloned with the addition of 50 and 30
BglII sites, and a Kozak sequence upstream of an N-terminal Myc tag from cDNA
derived from GM-CSF-derived bone marrow dendritic cells. The following primers
were used: forward, 50 -AATAAGATCTCCACCATGGCAGAACAGAAGCTCA
TTTCTGAAGAAGACTTGAACGAACGGA TCCCCAGCGC-30 , reverse, 50 -ATA
AAGATCTCCCTCCAGAGTTTAGTCTTTGGTTTCT-30 . The resulting
fragment was digested with BglII and cloned into the BglII site of the GFP-RV
vector which contains an internal ribosome entry sequence upstream of GFP70.
Retroviral vectors were transfected into Phoenix E cells by calcium phosphate
coprecipitation70, and viral supernatants were collected after 2 days of culture.
Magnetically puriﬁed total CD4 þ T cells (Invitrogen Dynabeads FlowComp
Mouse CD4 kit) were stimulated in TH1 or TH17 conditions, and viral supernatants
were used to infect T cells by spin infection at 2,000 r.p.m. in the presence of
2 mg ml  1 polybrene for 1 h on day 1 after activation. Cells were used for
intracellular ﬂow cytometry on day 4 of culture.
Statistical analysis. Differences between groups were analysed by an unpaired,
two-tailed Student’s t-test (Prism; GraphPad Software, Inc.), with Pr0.05 considered signiﬁcant.
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